<p>挪威银行在第二季度收购了 CRISPR Therapeutics AG（纳斯达克代码：CRSP - 免费报告）的新股份，根据该公司最近向证券交易委员会（SEC）披露的信息。该公司收购了 406,487 股，价值约为 19,772,000 美元。到最近的报告期末，挪威银行持有 CRISPR Therapeutics 约 0.45% 的股份。</p>
<p>获取 <strong>CRISPR Therapeutics</strong> 的提醒：</p>
<ul>
<li>CRSPR 股票可能准备兑现其巨大的承诺</li>
</ul>
<p>其他几家机构投资者和对冲基金最近也增加或减少了在 CRSP 的持股。IVC Wealth Advisors LLC 在第二季度购买了价值约 225,000 美元的 CRISPR Therapeutics 新股份。Koss Olinger Consulting LLC 在第二季度将其在 CRISPR Therapeutics 的持股增加了 29.8%。Koss Olinger Consulting LLC 现在拥有 42,197 股该公司的股票，价值 2,052,000 美元，此前在上个季度又收购了 9,685 股。先锋集团（Vanguard Group Inc.）在第一季度将其在 CRISPR Therapeutics 的持股提高了 1.9%。先锋集团现在拥有 1,769,709 股该公司的股票，价值 60,223,000 美元，此前在上个季度又收购了 33,711 股。Slow Capital Inc.在第二季度将其在 CRISPR Therapeutics 的持股增加了 15.6%。Slow Capital Inc.现在拥有 75,396 股该公司的股票，价值 3,667,000 美元，此前在上个季度又收购了 10,152 股。最后，Legal &amp; General Group Plc 在第二季度将其在 CRISPR Therapeutics 的持股增加了 59.7%。Legal &amp; General Group Plc 现在拥有 129,567 股该公司的股票，价值 6,302,000 美元，此前在上个季度又收购了 48,412 股。对冲基金和其他机构投资者持有该公司 69.20% 的股份。</p>
<h2>分析师设定新目标价</h2>
<p>几位分析师最近对该公司发表了评论。Wedbush 将 CRISPR Therapeutics 的目标价从 13.00 美元下调至 9.00 美元，并在 11 月 5 日的报告中给予该公司 “跑赢大盘” 的评级。富国银行（Wells Fargo &amp; Company）在 10 月 13 日的研究报告中设定了 CRISPR Therapeutics 的目标价为 75.00 美元。花旗集团在 11 月 11 日的报告中重申了 “买入” 评级，并将 CRISPR Therapeutics 的目标价下调至 77.00 美元（之前为 87.00 美元）。Weiss Ratings 在 10 月 8 日的研究报告中重申了 CRISPR Therapeutics 的 “卖出（d-）” 评级。最后，Robert W. Baird 在 11 月 11 日的研究报告中将 CRISPR Therapeutics 的目标价从 52.00 美元下调至 44.00 美元，并给予该公司 “中性” 评级。十一位投资分析师对该股票给予了买入评级，八位给予了持有评级，两位给予了卖出评级。根据 MarketBeat，该公司目前的平均评级为 “持有”，共识目标价为 67.42 美元。</p>
<ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
<p><strong>获取我们关于 CRISPR Therapeutics 的最新报告</strong></p>
<h2>CRISPR Therapeutics 价格表现</h2>
<p>纳斯达克 CRSP 周二开盘价为 57.36 美元。CRISPR Therapeutics AG 的 1 年最低价为 30.04 美元，1 年最高价为 78.48 美元。该公司的市值为 54.7 亿美元，市盈率为-10.26，贝塔值为 1.74。该公司的 50 日移动平均线为 61.17 美元，200 日移动平均线为 55.61 美元。</p>
<ul>
<li>2 只基因编辑股票在 2025 年有强劲反弹的潜力</li>
</ul>
<p>CRISPR Therapeutics（纳斯达克代码：CRSP - 获取免费报告）最近于 11 月 10 日发布了季度财报。该公司报告季度每股收益为（1.17 美元），超出分析师一致预期的（1.32 美元）0.15 美元。该季度的营业收入为 89 万美元，而分析师预期为 874 万美元。CRISPR Therapeutics 的股本回报率为-21.23%，净利润率为-1,273.70%。研究分析师预计 CRISPR Therapeutics AG 在本年度的每股收益为-5.16 美元。</p>
<h2>CRISPR Therapeutics 的内部活动</h2>
<p>在其他新闻中，首席执行官 Samarth Kulkarni 在 10 月 17 日（星期五）出售了 50,895 股公司的股票。股票以平均 67.91 美元的价格出售，总交易额为 3,456,279.45 美元。出售后，首席执行官持有 254,201 股公司的股票，价值 17,262,789.91 美元。这笔交易代表其持股减少了 16.68%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过此链接获取。此外，法律顾问 James R. Kasinger 在 10 月 14 日（星期二）出售了 1,076 股 CRISPR Therapeutics 的股票。股票以平均 66.60 美元的价格出售，总交易额为 71,661.60 美元。交易后，法律顾问直接持有 83,402 股公司的股票，价值约 5,554,573.20 美元。这笔交易代表其持股减少了 1.27%。有关此次出售的更多细节可在官方 SEC 披露中找到。在上个季度，内部人士共出售了 56,213 股公司股票，价值 3,810,458 美元。公司内部人士持有 4.10% 的股份。</p>
<h2>CRISPR Therapeutics 公司简介</h2>
<p>（免费报告）</p>
<p>CRISPR Therapeutics 是一家基因编辑公司，专注于利用其专有的 CRISPR/Cas9 平台开发变革性的基因治疗药物，以治疗严重疾病。CRISPR/Cas9 是一种革命性的基因编辑技术，允许对基因组 DNA 进行精确、定向的修改。CRISPR Therapeutics 已在包括血红蛋白病、肿瘤学、再生医学和罕见疾病等多个疾病领域建立了一系列治疗项目。</p>
<h2>特色故事</h2>
<ul>
<li>五只我们认为比 CRISPR Therapeutics 更好的股票</li>
<li>上海证券交易所综合指数是什么？</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑对消费者健康的启示</li>
<li>什么是股息挑战者？</li>
<li>2026 年最有可能拆分的三只股票</li>
<li>宠物是大生意：四只值得加入你投资组合的大型宠物股票</li>
<li>ChargePoint 的复苏故事：为什么这只电动车股票再次充满活力</li>
</ul>
<p><strong>想看看其他对 CRSP 感兴趣的对冲基金持有哪些股票吗？</strong> 访问 HoldingsChannel.com 获取 CRISPR Therapeutics AG（NASDAQ:CRSP - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 CRISPR Therapeutics 吗？</h2>
<p>在考虑 CRISPR Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 CRISPR Therapeutics 并不在名单上。</p>
<p>虽然 CRISPR Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CRISPR治疗

<p>挪威银行在 CRISPR Therapeutics AG 中获得了新的股份，在第二季度购买了价值 1977 万美元的 406,487 股。这项投资代表了 CRISPR Therapeutics 0.45% 的股权。其他机构投资者也调整了他们在该公司的股份。分析师对 CRISPR Therapeutics 的评级各不相同，普遍目标价为 67.42 美元。该公司报告了季度收益，超出预期，但利润率为负。首席执行官 Samarth Kulkarni 出售了股份，减少了 16.68% 的持股</p>

<p>Norges Bank acquired a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 406,487 shares of the company's stock, valued at approximately $19,772,000. Norges Bank owned approximately 0.45% of CRISPR Therapeutics at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>挪威银行在第二季度收购了 CRISPR Therapeutics AG（纳斯达克代码：CRSP - 免费报告）的新股份，根据该公司最近向证券交易委员会（SEC）披露的信息。该公司收购了 406,487 股，价值约为 19,772,000 美元。到最近的报告期末，挪威银行持有 CRISPR Therapeutics 约 0.45% 的股份。</p>
</div><p>Get <strong>CRISPR Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>CRISPR Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>CRSPR Stock Could Be Ready to Deliver on Its Massive Promise</li>
</ul>
<div class="lb-trans"><ul>
<li>CRSPR 股票可能准备兑现其巨大的承诺</li>
</ul>
</div><p>Several other institutional investors and hedge funds also recently added to or reduced their stakes in CRSP. IVC Wealth Advisors LLC bought a new stake in shares of CRISPR Therapeutics in the 2nd quarter valued at about $225,000. Koss Olinger Consulting LLC raised its stake in shares of CRISPR Therapeutics by 29.8% during the 2nd quarter. Koss Olinger Consulting LLC now owns 42,197 shares of the company's stock worth $2,052,000 after acquiring an additional 9,685 shares in the last quarter. Vanguard Group Inc. lifted its position in CRISPR Therapeutics by 1.9% during the first quarter. Vanguard Group Inc. now owns 1,769,709 shares of the company's stock valued at $60,223,000 after acquiring an additional 33,711 shares during the last quarter. Slow Capital Inc. boosted its stake in CRISPR Therapeutics by 15.6% in the second quarter. Slow Capital Inc. now owns 75,396 shares of the company's stock valued at $3,667,000 after acquiring an additional 10,152 shares in the last quarter. Finally, Legal &amp; General Group Plc boosted its stake in CRISPR Therapeutics by 59.7% in the second quarter. Legal &amp; General Group Plc now owns 129,567 shares of the company's stock valued at $6,302,000 after acquiring an additional 48,412 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金最近也增加或减少了在 CRSP 的持股。IVC Wealth Advisors LLC 在第二季度购买了价值约 225,000 美元的 CRISPR Therapeutics 新股份。Koss Olinger Consulting LLC 在第二季度将其在 CRISPR Therapeutics 的持股增加了 29.8%。Koss Olinger Consulting LLC 现在拥有 42,197 股该公司的股票，价值 2,052,000 美元，此前在上个季度又收购了 9,685 股。先锋集团（Vanguard Group Inc.）在第一季度将其在 CRISPR Therapeutics 的持股提高了 1.9%。先锋集团现在拥有 1,769,709 股该公司的股票，价值 60,223,000 美元，此前在上个季度又收购了 33,711 股。Slow Capital Inc.在第二季度将其在 CRISPR Therapeutics 的持股增加了 15.6%。Slow Capital Inc.现在拥有 75,396 股该公司的股票，价值 3,667,000 美元，此前在上个季度又收购了 10,152 股。最后，Legal &amp; General Group Plc 在第二季度将其在 CRISPR Therapeutics 的持股增加了 59.7%。Legal &amp; General Group Plc 现在拥有 129,567 股该公司的股票，价值 6,302,000 美元，此前在上个季度又收购了 48,412 股。对冲基金和其他机构投资者持有该公司 69.20% 的股份。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several analysts have recently commented on the company. Wedbush decreased their price objective on CRISPR Therapeutics from $13.00 to $9.00 and set an &#34;outperform&#34; rating for the company in a report on Wednesday, November 5th. Wells Fargo &amp; Company set a $75.00 price target on CRISPR Therapeutics in a research note on Monday, October 13th. Citigroup reissued a &#34;buy&#34; rating and issued a $77.00 price target (down previously from $87.00) on shares of CRISPR Therapeutics in a report on Tuesday, November 11th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of CRISPR Therapeutics in a research note on Wednesday, October 8th. Finally, Robert W. Baird decreased their price objective on shares of CRISPR Therapeutics from $52.00 to $44.00 and set a &#34;neutral&#34; rating for the company in a research report on Tuesday, November 11th. Eleven investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of &#34;Hold&#34; and a consensus target price of $67.42.</p>
<div class="lb-trans"><p>几位分析师最近对该公司发表了评论。Wedbush 将 CRISPR Therapeutics 的目标价从 13.00 美元下调至 9.00 美元，并在 11 月 5 日的报告中给予该公司 “跑赢大盘” 的评级。富国银行（Wells Fargo &amp; Company）在 10 月 13 日的研究报告中设定了 CRISPR Therapeutics 的目标价为 75.00 美元。花旗集团在 11 月 11 日的报告中重申了 “买入” 评级，并将 CRISPR Therapeutics 的目标价下调至 77.00 美元（之前为 87.00 美元）。Weiss Ratings 在 10 月 8 日的研究报告中重申了 CRISPR Therapeutics 的 “卖出（d-）” 评级。最后，Robert W. Baird 在 11 月 11 日的研究报告中将 CRISPR Therapeutics 的目标价从 52.00 美元下调至 44.00 美元，并给予该公司 “中性” 评级。十一位投资分析师对该股票给予了买入评级，八位给予了持有评级，两位给予了卖出评级。根据 MarketBeat，该公司目前的平均评级为 “持有”，共识目标价为 67.42 美元。</p>
</div><ul>
<li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
</div><p><strong>Get Our Latest Report on CRISPR Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 CRISPR Therapeutics 的最新报告</strong></p>
</div><h2>CRISPR Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>CRISPR Therapeutics 价格表现</h2>
</div><p>NASDAQ CRSP opened at $57.36 on Tuesday. CRISPR Therapeutics AG has a 1 year low of $30.04 and a 1 year high of $78.48. The company has a market capitalization of $5.47 billion, a PE ratio of -10.26 and a beta of 1.74. The company has a fifty day moving average of $61.17 and a 200 day moving average of $55.61.</p>
<div class="lb-trans"><p>纳斯达克 CRSP 周二开盘价为 57.36 美元。CRISPR Therapeutics AG 的 1 年最低价为 30.04 美元，1 年最高价为 78.48 美元。该公司的市值为 54.7 亿美元，市盈率为-10.26，贝塔值为 1.74。该公司的 50 日移动平均线为 61.17 美元，200 日移动平均线为 55.61 美元。</p>
</div><ul>
<li>2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只基因编辑股票在 2025 年有强劲反弹的潜力</li>
</ul>
</div><p>CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings data on Monday, November 10th. The company reported ($1.17) earnings per share for the quarter, beating analysts' consensus estimates of ($1.32) by $0.15. The business had revenue of $0.89 million during the quarter, compared to analyst estimates of $8.74 million. CRISPR Therapeutics had a negative return on equity of 21.23% and a negative net margin of 1,273.70%. Research analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.</p>
<div class="lb-trans"><p>CRISPR Therapeutics（纳斯达克代码：CRSP - 获取免费报告）最近于 11 月 10 日发布了季度财报。该公司报告季度每股收益为（1.17 美元），超出分析师一致预期的（1.32 美元）0.15 美元。该季度的营业收入为 89 万美元，而分析师预期为 874 万美元。CRISPR Therapeutics 的股本回报率为-21.23%，净利润率为-1,273.70%。研究分析师预计 CRISPR Therapeutics AG 在本年度的每股收益为-5.16 美元。</p>
</div><h2>Insider Activity at CRISPR Therapeutics</h2>
<div class="lb-trans"><h2>CRISPR Therapeutics 的内部活动</h2>
</div><p>In other news, CEO Samarth Kulkarni sold 50,895 shares of the firm's stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $67.91, for a total transaction of $3,456,279.45. Following the sale, the chief executive officer owned 254,201 shares of the company's stock, valued at $17,262,789.91. This trade represents a 16.68% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, General Counsel James R. Kasinger sold 1,076 shares of CRISPR Therapeutics stock in a transaction that occurred on Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total transaction of $71,661.60. Following the transaction, the general counsel directly owned 83,402 shares of the company's stock, valued at approximately $5,554,573.20. This trade represents a 1.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 56,213 shares of company stock valued at $3,810,458. 4.10% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他新闻中，首席执行官 Samarth Kulkarni 在 10 月 17 日（星期五）出售了 50,895 股公司的股票。股票以平均 67.91 美元的价格出售，总交易额为 3,456,279.45 美元。出售后，首席执行官持有 254,201 股公司的股票，价值 17,262,789.91 美元。这笔交易代表其持股减少了 16.68%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过此链接获取。此外，法律顾问 James R. Kasinger 在 10 月 14 日（星期二）出售了 1,076 股 CRISPR Therapeutics 的股票。股票以平均 66.60 美元的价格出售，总交易额为 71,661.60 美元。交易后，法律顾问直接持有 83,402 股公司的股票，价值约 5,554,573.20 美元。这笔交易代表其持股减少了 1.27%。有关此次出售的更多细节可在官方 SEC 披露中找到。在上个季度，内部人士共出售了 56,213 股公司股票，价值 3,810,458 美元。公司内部人士持有 4.10% 的股份。</p>
</div><h2>CRISPR Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>CRISPR Therapeutics 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.</p>
<div class="lb-trans"><p>CRISPR Therapeutics 是一家基因编辑公司，专注于利用其专有的 CRISPR/Cas9 平台开发变革性的基因治疗药物，以治疗严重疾病。CRISPR/Cas9 是一种革命性的基因编辑技术，允许对基因组 DNA 进行精确、定向的修改。CRISPR Therapeutics 已在包括血红蛋白病、肿瘤学、再生医学和罕见疾病等多个疾病领域建立了一系列治疗项目。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than CRISPR Therapeutics</li>
<li>What is the Shanghai Stock Exchange Composite Index?</li>
<li>What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health</li>
<li>What Are Dividend Challengers?</li>
<li>3 Stocks Most Likely to Split in 2026</li>
<li>Pets Are Big Business: 4 Big-Ticket Pet Stocks to Add to Your Portfolio</li>
<li>ChargePoint's Comeback Story: Why This EV Stock Is Charging Up Again</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 CRISPR Therapeutics 更好的股票</li>
<li>上海证券交易所综合指数是什么？</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑对消费者健康的启示</li>
<li>什么是股息挑战者？</li>
<li>2026 年最有可能拆分的三只股票</li>
<li>宠物是大生意：四只值得加入你投资组合的大型宠物股票</li>
<li>ChargePoint 的复苏故事：为什么这只电动车股票再次充满活力</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding CRSP?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 CRSP 感兴趣的对冲基金持有哪些股票吗？</strong> 访问 HoldingsChannel.com 获取 CRISPR Therapeutics AG（NASDAQ:CRSP - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=CRSP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CRISPR Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 CRISPR Therapeutics 吗？</h2>
</div><p>Before you consider CRISPR Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 CRISPR Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 CRISPR Therapeutics 并不在名单上。</p>
</div><p>While CRISPR Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 CRISPR Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

挪威银行向 CRISPR Therapeutics AG 投资 1977 万美元